These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 26383000)

  • 21. What goes up must come down: biomarkers and novel biologicals in severe asthma.
    Hilvering B; Pavord ID
    Clin Exp Allergy; 2015 Jul; 45(7):1162-9. PubMed ID: 25640208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal Antibodies for the Management of Severe Asthma.
    Rubinsztajn R; Chazan R
    Adv Exp Med Biol; 2016; 935():35-42. PubMed ID: 27334730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
    Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
    Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting T cells for asthma.
    Heijink IH; Van Oosterhout AJ
    Curr Opin Pharmacol; 2005 Jun; 5(3):227-31. PubMed ID: 15907907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
    Wu AY; Sur S; Grant JA; Tripple JW
    Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
    Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
    Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease.
    Mitchell J; Dimov V; Townley RG
    Curr Opin Investig Drugs; 2010 May; 11(5):527-34. PubMed ID: 20419598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
    Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
    J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of asthma endotypes: implications for therapy.
    Stokes JR; Casale TB
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):121-5. PubMed ID: 27499539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytokine-directed therapy in asthma.
    Ichinose M; Barnes PJ
    Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):263-9. PubMed ID: 15379594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.
    Wenzel S; Wilbraham D; Fuller R; Getz EB; Longphre M
    Lancet; 2007 Oct; 370(9596):1422-31. PubMed ID: 17950857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-IgE and other antibody targets in asthma.
    Singh J; Kraft M
    Handb Exp Pharmacol; 2008; (181):257-88. PubMed ID: 18071950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omalizumab in asthma: an update on recent developments.
    Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
    J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-interleukin therapy in asthma.
    Dunn RM; Wechsler ME
    Clin Pharmacol Ther; 2015 Jan; 97(1):55-65. PubMed ID: 25670383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Targeted asthma therapies: confirmations, hopes, and disappointments].
    Schleich F; Louis R
    Rev Med Liege; 2012; 67 Spec No():14-21. PubMed ID: 22690481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.
    Pelaia C; Vatrella A; Bruni A; Terracciano R; Pelaia G
    Drug Des Devel Ther; 2018; 12():619-628. PubMed ID: 29606855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.